Antibiotic engine

A combination of non-dilutive funding and a newly-raised $31.9 million series B-1 round should give Entasis Therapeutics Inc. enough cash to see its lead candidate all the way through commercialization and to move two others to their next milestones.

The company's B-1 extension round closed on Sept. 5 with participation from new investors Pivotal bioVenture Partners, Sofinnova Ventures and TPG Biotech, and follows a $50 million series B raised in 2016. ...